Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1Breast 1

Conditions

Breast Neoplasms 22Neoplasm Metastasis 3Brain Neoplasms 3Stomach Neoplasms 2Sarcoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Colorectal Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Pathologic Complete Response 1Lung Neoplasms 1HER2-positive Breast Cancer 1Esophageal Neoplasms 1Endometrial Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Central Nervous System Diseases 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms, Male 1

Interventions

sodium thiosulfate 1Tretinoin 1Trastuzumab 1Mitoxantrone 1Methotrexate 1Cytarabine 1Carboplatin 1Amifostine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Drug-Related Side Effects and Adverse Reactions × Trastuzumab × Clear all
NCT00397501 2017-04-21

BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain

OHSU Knight Cancer Institute

Phase 1/2 Withdrawn
BreastCNS

Brain Neoplasms, Breast Neoplasms, Central Nervous System Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡